Christopher Copenhaver, MD
Allergy & Immunology · Asheville, NCNPI 1659370708
Payments from drug & device makers
Across 635 payments — averaging $138.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$40K
- AstraZeneca$32K
- Novartis$8K
- Sanofi$1K
- CSL Behring$1K
- Takeda Pharmaceuticals U.S.A., Inc.$787
- plus $5K from 27 others
What the payments were for
- Consulting fees$7,4008%
- Speaking & faculty fees$65,85075%
- Travel & lodging$4581%
- Food & beverage$14,29816%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $39,717 |
| AstraZeneca | 116 | $32,097 |
| Novartis | 10 | $7,645 |
| Sanofi | 70 | $1,458 |
| CSL Behring | 43 | $1,031 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $787 |
| Regeneron Healthcare Solutions, Inc. | 28 | $749 |
| Aimmune Therapeutics, Inc. | 5 | $551 |
| Amgen(2 entities) | 23 | $549 |
| Pfizer | 28 | $489 |
| Biocryst US Sales Co., LLC | 20 | $433 |
| Grifols USA, LLC | 18 | $414 |
| Genentech USA, Inc. | 18 | $305 |
| ARS Pharmaceuticals Operations, Inc. | 15 | $299 |
| Pharming Healthcare, Inc. | 13 | $281 |
| Hospira, Inc. | 11 | $195 |
| Alk-abello, Inc | 10 | $191 |
| Kaleo, Inc. | 10 | $156 |
| Sanofi US Services Inc. | 1 | $135 |
| Optinose US, Inc. | 8 | $134 |
| Blueprint Medicines Corporation | 3 | $98 |
| Ionis Pharmaceuticals, Inc. | 4 | $96 |
| Boehringer Ingelheim | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 5 | $75 |
| ADMA Biomanufacturing LLC | 2 | $38 |
| Covis Pharma GmbH | 2 | $26 |
| Insmed, Inc. | 1 | $25 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Organon | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Merck | 1 | $15 |
| Octapharma USA, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,153 in reported general payments places this provider in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $101,939 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $71,236 |
| SymbicortBudesonide/Formoterol Fumarate | 87 | $28,363 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $23,248 |
| Ipratropium Bromide | 226 | $14,498 |
| DuleraMometasone/Formoterol | 36 | $12,849 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $12,807 |
| Spiriva RespimatTiotropium Bromide | 17 | $12,105 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $11,408 |
| Epinephrine | 54 | $9,620 |
| Arnuity ElliptaFluticasone Furoate | 31 | $9,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,120 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $6,558 |
| Azelastine Hcl | 161 | $5,793 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $4,578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $39,717 | $104,043151 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $32,097 | $36,482100 claims |
| MerckDulera | $15 | $12,84936 claims |
| Boehringer IngelheimSpiriva Respimat | $82 | $12,10517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Asheville
- David CypcarAsheville$1.6M
- William McCannAsheville$710K
- David BrownAsheville$129K
- Elise CoulsonAsheville$16K
- Jordan SmallwoodAsheville$13K
- John van WyeAsheville$11K
- Craig LaforceRaleigh$7.9M
- Karen DunnRaleigh$3.3M
- Maeve OconnorCharlotte$2.2M
- Edwin KimChapel Hill$874K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.